Category: Press Release

BIOVECTRA is Honoured With 2025 CDMO Leadership Award, Biologics — Industry Recognizes BIOVECTRA’s Excellence in Microbial Fermentation, Recombinant Protein Production, and Aseptic Fill-Finish Capabilities.

Posted on by BIOVECTRA
Geometric logo featuring teal triangles beside bold text reading "CDMO Leadership Awards 2025" on a plain white background.

CHARLOTTETOWN, Prince Edward Island – BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as […]

Read More…

Agilent Completes Acquisition of BIOVECTRA

Posted on by BIOVECTRA
Agilent logo featuring a blue starburst design on the left and the company name in black text on the right against a white background.

  Pharmaceutical customers will benefit from a broader set of specialized CDMO capabilities SANTA CLARA, California, September 20, 2024 – Agilent Technologies Inc. (NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules […]

Read More…

Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care

Posted on by BIOVECTRA
Modern industrial building with "BIOVECTRA" signage. Two flags, including Canadian, are visible. Parking area and clear blue sky in the background.

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of […]

Read More…

BIOVECTRA Launches Specialized Capabilities in mRNA Drug Product Development and Biomanufacturing

Posted on by BIOVECTRA
Two people in lab coats and safety glasses work with scientific equipment and a tablet in a modern laboratory setting.

CHARLOTTETOWN, PRINCE EDWARD ISLAND, November 17th, 2023 –  Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island. “This expansion places BIOVECTRA at the forefront of supporting the next generation of treatments for today’s […]

Read More…

BIOVECTRA Signs Service Agreement with Acuitas Therapeutics for Unique Lipid Nanoparticle (LNP) Delivery System Used in Manufacturing mRNA-Based Therapies

Posted on by BIOVECTRA
Logos of Biovectra and Acuitas Therapeutics with distinct designs; Biovectra in purple, blue, yellow; Acuitas features a green circle with white symbol.

CHARLOTTETOWN, Prince Edward Island and VANCOUVER, British Columbia, October 5, 2023 – BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics. “We are thrilled about this partnership with Acuitas […]

Read More…

BIOVECTRA Welcomes Normand Blais to Senior Director, Development & Innovation, Biologics Role

Posted on by BIOVECTRA
A person with gray hair and glasses is smiling, wearing a blue suit and white shirt against a plain white background.

  Charlottetown, P.E.I. (January 18, 2023) – BIOVECTRA is pleased to announce that Normand Blais was appointed as Senior Director, Development & Innovation, Biologics.  Reporting to the Chief Science Officer, Mr. Blais will be responsible for the strategic direction shaping BIOVECTRA’s pDNA & mRNA vaccine process science program. Mr. Blais is accomplished in early-candidate vaccine […]

Read More…

BIOVECTRA Named One of Canada’s Top Employers Again in 2023

Posted on by BIOVECTRA
Three people are sitting at a table, smiling and engaged in a meeting or discussion, with notebooks and pens visible.

  Charlottetown, P.E.I. (November 22, 2022) – BIOVECTRA was selected as one of Canada’s Top 100 Employers for a second consecutive year and is considered amongst the country’s leading workplaces. BIOVECTRA is a fast growing, forward-thinking contract development, and manufacturing organization (CDMO) solving complex challenges to improve patient care for some of the world’s top […]

Read More…

BIOVECTRA Expands Manufacturing Capacity with Single-Use Microbial Fermentation Technology

Posted on by BIOVECTRA
A spacious industrial lab with large stainless steel tanks and complex control panels featuring digital displays and connecting tubes.

  Charlottetown, CANADA, October 31, 2022 – BIOVECTRA is ready to accept projects at its manufacturing facility in Windsor, Nova Scotia, Canada, for its new, single-use biologics fermentation suite. Containing 100 L and 1,000 L single-use fermenters, this state-of-the-art process train enhances BIOVECTRA’s microbial fermentation overall network of capacity and allows BIOVECTRA to support even […]

Read More…

BIOVECTRA Named to True North List of Leading Canadian Companies

Posted on by BIOVECTRA
A person presents at a conference. A screen displays various Canadian companies' locations. Audience members watch attentively in a well-lit room.

  CHARLOTTETOWN, PEI – BIOVECTRA was recently named to Communitech’s True North list as one of Canada’s high performing tech companies that has a promising growth trajectory. Team True North is a roster of Canadian innovation companies shown by verified data to have the highest probability of reaching $1B in revenue. As global markets experience […]

Read More…

BIOVECTRA Starts Construction on its Charlottetown mRNA Biomanufacturing Centre

Posted on by BIOVECTRA
A group of eleven people in hard hats participate in a groundbreaking ceremony at a future vaccine and biomanufacturing center site.

  Charlottetown, P.E.I. (April 14, 2022) – BIOVECTRA broke ground today, with help from provincial and federal officials, on a cutting-edge facility that will manufacture mRNA vaccines and therapeutics starting in 2023. BIOVECTRA’s mRNA Vaccine and Biomanufacturing Centre will add 36,000 square feet to its existing Charlottetown campus and, when operational, the cGMP facility will […]

Read More…

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors